Reports
Review, manage, and schedule Medical Affairs reports
All Reports
Showing 9 of 9 reportsUS National Thoracic Oncology MSL Territory & Biomarker Intelligence Report — Q3 2026
Comprehensive US national territory strategy covering 4 flagship NCI Comprehensive Cancer Centers (MD Anderson, MSKCC, Dana-Farber, City of Hope), NGS diagnostic turnaround metrics, and EGFR/KRAS trial support.
US Payer & P&T Committee Access Report — Targeted Immunotherapies & ADCs (2026)
Strategic US health economics & medical outcomes evaluation across major US payer networks (Kaiser Permanente, Elevance Health, UnitedHealth Group, Aetna, CVS Caremark) for oncology formulary positioning.
US Key Opinion Leader Scientific Exchange & Trial Site Support Report
National scientific profiling and engagement strategy for top US NCI Comprehensive Cancer Center investigators across Phase II/III oncology clinical trial sites.
US Oncology Safety & Adverse Event Field Insights Digest — H2 2026
Aggregated H2 2026 field observations from 240 US MSL HCP exchanges on managing Grade 3+ pneumonitis, dermatologic toxicities, and infusion-related reactions in real-world clinical practice.
Northwest MSL Territory Plan — H1 2026
Strategic engagement plan for the Northwest MSL territory covering Oncology, Cardiology, and Immunology KOLs across 4 flagship academic centres.
Kaiser Account Plan — Easton Academic Medical Centre
Integrated account strategy for Easton Academic Medical Centre (Kaiser network), covering stakeholder mapping, treatment landscape, and 12-month engagement plan.
National Oncology KOL Profile — Assoc. Prof. Sofia Evans
Comprehensive intelligence profile of Assoc. Prof. Sofia Evans, a nationally recognised leader in Oncology at St. Victoria Hospital.
Monthly Field Insights Report — June 2026
Aggregated field intelligence for June 2026, covering 128 MSL interactions, competitor activity, emerging literature, and KOL sentiment across the cardiovascular and oncology franchises.
MSL Scientific Exchange Report — Advisory Board, June 2026
Summary of the June 18 advisory board convened to review emerging biomarker data and inform 2026–2027 medical strategy.